Travere Therapeutics, Inc. TVTX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $78.36M-15.8% | $93.04M-16.1% | $110.93M+47.6% | $75.15M+21.4% | $61.9M+5.7% | ||
| —— | —— | —— | —— | —— | ||
| $87.3M+8.9% | $80.13M-3.4% | $82.98M+114% | $38.72M+12.6% | $34.38M+26.8% | ||
| $30.7M+1.4% | $30.28M-5.4% | $32M-4.7% | $33.59M-1.4% | $34.07M-4.4% | ||
| $34.35M+19.4% | $28.76M+2.5% | $28.05M+62.9% | $17.22M+26.5% | $13.62M+7.3% | ||
| $392.68M-10.3% | $437.57M+17.9% | $371.11M-2.2% | $379.57M+1.4% | $374.17M-10.2% | ||
| $3.63M-9.8% | $4.02M-6.9% | $4.32M-5.3% | $4.56M-6.0% | $4.85M-9.1% | ||
| $9.67M-8.6% | $10.58M-7.7% | $11.46M-7.1% | $12.34M-6.5% | $13.2M-7.7% | ||
| $110.04M-3.4% | $113.87M+4.1% | $109.44M+3.6% | $105.61M+1.7% | $103.82M-0.2% | ||
| $8.48M-4.5% | $8.88M-13.4% | $10.25M-47.8% | $19.65M+5.1% | $18.69M+2.9% | ||
| $555.19M-8.3% | $605.19M+12.4% | $538.58M-3.0% | $555.31M+1.2% | $548.8M-7.6% | ||
| $12.91M-47.9% | $24.8M+36.1% | $18.23M-4.8% | $19.13M+24.5% | $15.37M-34.7% | ||
| $2.1M-34.3% | $3.19M-40.3% | $5.35M-62.5% | $14.29M-9.3% | $15.76M-7.9% | ||
| $6.02M+2.4% | $5.88M+2.5% | $5.73M+2.5% | $5.6M+2.5% | $5.46M+1.0% | ||
| $125.44M-21.6% | $159.9M+18.4% | $135.07M-28.7% | $189.54M+3.9% | $182.46M-9.1% | ||
| $9.57M-14.1% | $11.13M-11.9% | $12.65M-10.5% | $14.12M-9.4% | $15.58M-9.4% | ||
| $15.58M-8.4% | $17.01M-7.5% | $18.38M-6.8% | $19.72M-6.3% | $21.04M-6.9% | ||
| $9.38M+23.4% | $7.6M+28.2% | $5.93M-24.8% | $7.88M+8.4% | $7.27M+7.0% | ||
| $456.46M-6.9% | $490.36M+5.5% | $465.02M-11.0% | $522.56M+1.3% | $515.98M-3.6% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | ||
| $1.61B+1.3% | $1.59B+2.5% | $1.55B+1.0% | $1.53B+0.8% | $1.52B+1.0% | ||
| -$1.51B-2.5% | -$1.47B+0.2% | -$1.48B+1.7% | -$1.5B-0.9% | -$1.49B-2.8% | ||
| -$1.06M+10.7% | -$1.19M-12.8% | -$1.05M-29.8% | -$812K+3.7% | -$843K-954% | ||
| $98.73M-14.0% | $114.83M+56.1% | $73.56M+125% | $32.75M-0.2% | $32.82M-44.4% | ||
| $555.19M-8.3% | $605.19M+12.4% | $538.58M-3.0% | $555.31M+1.2% | $548.8M-7.6% | ||
| $186.31M-18.9% | $229.76M+60.0% | $143.6M-41.2% | $244.38M-6.1% | $260.35M-16.6% | ||
| —— | —— | —— | —— | —— | ||
| $8.48M-4.5% | $8.88M-13.4% | $10.25M-47.8% | $19.65M+5.1% | $18.69M+2.9% | ||
| $9.67M-8.6% | $10.58M-7.7% | $11.46M-7.1% | $12.34M-6.5% | $13.2M-7.7% | ||
| $110.04M-3.4% | $113.87M+4.1% | $109.44M+3.6% | $105.61M+1.7% | $103.82M-0.2% | ||
| $9.67M-8.6% | $10.58M-7.7% | $11.46M-7.1% | $12.34M-6.5% | $13.2M-7.7% | ||
| $8.48M-4.5% | $8.88M-13.4% | $10.25M-47.8% | $19.65M+5.1% | $18.69M+2.9% | ||
| $9.67M-8.6% | $10.58M-7.7% | $11.46M-7.1% | $12.34M-6.5% | $13.2M-7.7% | ||
| $8.48M-4.5% | $8.88M-13.4% | $10.25M-47.8% | $19.65M+5.1% | $18.69M+2.9% | ||
| $104.41M-17.2% | $126.04M+19.2% | $105.76M+29.5% | $81.68M+5.9% | $77.11M-10.4% | ||
| —— | —— | —— | —— | —— | ||
| $104.41M-17.2% | $126.04M+19.2% | $105.76M+29.5% | $81.68M+5.9% | $77.11M-10.4% | ||
| $2.1M-34.3% | $3.19M-40.3% | $5.35M-62.5% | $14.29M-9.3% | $15.76M-7.9% | ||
| $15.58M-8.4% | $17.01M-7.5% | $18.38M-79.2% | $88.56M-1.4% | $89.8M-1.6% | ||
| $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $186.31M-18.9% | $229.76M+60.0% | $143.6M-41.2% | $244.38M-6.1% | $260.35M-16.6% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Travere Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 3.13 — current assets exceed current liabilities.
- Where does Travere Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.